Berberine interacts with gut microbiota and its potential therapy for polycystic ovary syndrome

被引:2
|
作者
Zhu, Ting-Wei [1 ,2 ,3 ]
Li, Xue-Lian [1 ,2 ,3 ]
机构
[1] Fudan Univ, Obstet & Gynecol Hosp, Shanghai 200011, Peoples R China
[2] Fudan Univ, Obstet & Gynecol Hosp, Shanghai Key Lab Female Reprod Endocrine Related D, Shanghai, Peoples R China
[3] Shanghai Urogenital Syst Dis Res Ctr 2022ZZ01012, Shanghai Clin Res Ctr Gynecol Dis 22MC1940200, Shanghai, Peoples R China
关键词
berberine; gut microbiota; insulin resistance; polycystic ovary syndrome; METABOLITES; DYSBIOSIS; BILE;
D O I
10.1111/1440-1681.13814
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Berberine (BBR) is an isoquinoline alkaloid extracted from Chinese medicinal plants showing a tight correlation with gut microbiota. Polycystic ovary syndrome (PCOS) is a prevalent reproductive and endocrine disorder syndrome among women of childbearing age. Dysbiosis, the imbalance of intestinal microorganisms, is a potential factor that takes part in the pathogenesis of PCOS. Recent evidence indicates that berberine offers promise for treating PCOS. Here, we review the recent research on the interaction between berberine and intestinal microorganisms, including the changes in the structure of gut bacteria, the intestinal metabolites after BBR treatment, and the effect of gut microbiota on the bioavailability of BBR. We also discuss the therapeutic effect of BBR on PCOS in terms of gut microbiota and its potential mechanisms.
引用
收藏
页码:835 / 843
页数:9
相关论文
共 50 条
  • [1] A New Approach to Polycystic Ovary Syndrome: The Gut Microbiota
    Yurtdas, Gamze
    Akdevelioglu, Yasemin
    JOURNAL OF THE AMERICAN COLLEGE OF NUTRITION, 2020, 39 (04) : 371 - 382
  • [2] Potential therapeutic application and mechanism of gut microbiota-derived extracellular vesicles in polycystic ovary syndrome
    Yang, Liangliang
    Liu, Tingxiu
    Liao, Yan
    Ren, Yuehan
    Zheng, Zheng
    Zhang, Mingyue
    Yu, Yue
    Liu, Chang
    Wang, Chaoying
    Chen, Tong
    Zhang, Lili
    Zheng, Dongxue
    Zhao, Haidan
    Ni, Zhexin
    Liu, Xinmin
    BIOMEDICINE & PHARMACOTHERAPY, 2024, 180
  • [3] Gut Microbiota in Patients with Polycystic Ovary Syndrome: a Systematic Review
    Guo, Jingbo
    Shao, Jie
    Yang, Yuan
    Niu, Xiaodan
    Liao, Juan
    Zhao, Qing
    Wang, Donghui
    Li, Shuaitong
    Hu, Junping
    REPRODUCTIVE SCIENCES, 2022, 29 (01) : 69 - 83
  • [4] Evaluating the therapeutic potential of moxibustion on polycystic ovary syndrome: a rat model study on gut microbiota and metabolite interaction
    Lin, Yong
    Zeng, Huiling
    Lin, Jieying
    Peng, Yiwei
    Que, Xueyun
    Wang, Lijun
    Chen, Ling
    Bai, Ni
    FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY, 2024, 14
  • [5] Gut microbiota alterations reveal potential gut–brain axis changes in polycystic ovary syndrome
    Z. Liang
    N. Di
    L. Li
    D. Yang
    Journal of Endocrinological Investigation, 2021, 44 : 1727 - 1737
  • [6] Characterization of the gut microbiota in polycystic ovary syndrome with dyslipidemia
    Yang, Tianjin
    Li, Guanjian
    Xu, Yuping
    He, Xiaojin
    Song, Bing
    Cao, Yunxia
    BMC MICROBIOLOGY, 2024, 24 (01):
  • [7] Gut microbiota: a hidden player in polycystic ovary syndrome
    Harshini Senthilkumar
    Mohanapriya Arumugam
    Journal of Translational Medicine, 23 (1)
  • [8] Gut Microbiota Modulation by Inulin Improves Metabolism and Ovarian Function in Polycystic Ovary Syndrome
    Geng, Lulu
    Yang, Xin
    Sun, Jiani
    Ran, Ximing
    Zhou, Dan
    Ye, Mingming
    Wen, Li
    Wang, Ruirui
    Chen, Miaoxin
    ADVANCED SCIENCE, 2025,
  • [9] Exploration of the pathogenesis of polycystic ovary syndrome based on gut microbiota: A review
    Guo, Hua
    Luo, Jing
    Lin, Hanmei
    MEDICINE, 2023, 102 (50) : E36075
  • [10] Gut microbiota alterations reveal potential gut-brain axis changes in polycystic ovary syndrome
    Liang, Z.
    Di, N.
    Li, L.
    Yang, D.
    JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 2021, 44 (08) : 1727 - 1737